.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Merck
Novartis
Mallinckrodt
Queensland Health
US Department of Justice
Baxter
Colorcon
AstraZeneca
McKesson

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,303,640

« Back to Dashboard

Which drugs does patent 6,303,640 protect, and when does it expire?


Patent 6,303,640 protects ACTOS, DUETACT, KAZANO, NESINA, and OSENI, and is included in five NDAs. There have been zero Paragraph IV challenges on Kazano, Nesina, and Duetact.

This patent has seventy-one patent family members in twenty-five countries.

Summary for Patent: 6,303,640

Title: Pharmaceutical composition
Abstract:Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
Inventor(s): Ikeda; Hitoshi (Higashiosaka, JP), Sohda; Takashi (Takatsuki, JP), Odaka; Hiroyuki (Kobe, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:09/605,704
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms UsaACTOSpioglitazone hydrochlorideTABLET;ORAL021073-001Jul 15, 1999ABRXYesNo► Subscribe► SubscribeMETHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER► Subscribe
Takeda Pharms UsaACTOSpioglitazone hydrochlorideTABLET;ORAL021073-002Jul 15, 1999ABRXYesNo► Subscribe► SubscribeMETHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER► Subscribe
Takeda Pharms UsaACTOSpioglitazone hydrochlorideTABLET;ORAL021073-003Jul 15, 1999ABRXYesYes► Subscribe► SubscribeMETHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER► Subscribe
Takeda Pharms UsaDUETACTglimepiride; pioglitazone hydrochlorideTABLET;ORAL021925-001Jul 28, 2006ABRXYesYes► Subscribe► SubscribeAS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES► Subscribe
Takeda Pharms UsaDUETACTglimepiride; pioglitazone hydrochlorideTABLET;ORAL021925-002Jul 28, 2006ABRXYesNo► Subscribe► SubscribeAS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013RXYesYes► Subscribe► SubscribeMETHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► SubscribeMETHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER► Subscribe
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-001Jan 25, 2013RXYesNo► Subscribe► SubscribeMETHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER► Subscribe
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-002Jan 25, 2013RXYesNo► Subscribe► SubscribeMETHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER► Subscribe
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-003Jan 25, 2013RXYesYes► Subscribe► SubscribeMETHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,303,640

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,211,205 Pharmaceutical composition► Subscribe
6,172,090 Pharmaceutical composition► Subscribe
6,133,293 Pharmaceutical composition► Subscribe
6,211,207 Pharmaceutical composition► Subscribe
6,599,923 Pharmaceutical composition► Subscribe
6,911,459 Pharmaceutical composition► Subscribe
6,169,100 Pharmaceutical composition► Subscribe
6,384,062 Pharmaceutical composition► Subscribe
6,329,404 Pharmaceutical composition► Subscribe
6,166,042 Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,303,640

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany69637988► Subscribe
Russian Federation2223760► Subscribe
Russian Federation2198682► Subscribe
Portugal1174135► Subscribe
Portugal861666► Subscribe
Norway2007007► Subscribe
Norway2007001► Subscribe
Norway317341► Subscribe
Norway314065► Subscribe
Norway20021172► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
Boehringer Ingelheim
Argus Health
Merck
Federal Trade Commission
Express Scripts
Mallinckrodt
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot